Limited Liver or Lung Colorectal Cancer Metastases. Systemic Treatment, Surgery, Ablation or SBRT

The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiat...

Descripción completa

Detalles Bibliográficos
Autores: Mollà, Meritxell|||0000-0001-6215-2251, Fernández Plana, Julen, Albiol, Santiago, Fondevila, Constantino|||0000-0002-6161-6824, Vollmer, Ivan|||0000-0002-8051-3994, Cases, Carla|||0000-0003-2110-9016, García-Criado, A.|||0000-0003-3536-4288, Capdevila Castillón, Jaume|||0000-0003-0718-8619, Conill, Carlos|||0000-0002-1599-6918, Fundora Suarez, Yiliam|||0000-0003-4950-6988, Fernández-Martos, Carlos, Pineda, Estela|||0000-0003-2128-747X
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:255651
Acceso en línea:https://ddd.uab.cat/record/255651
https://dx.doi.org/urn:doi:10.3390/jcm10102131
Access Level:acceso abierto
Palabra clave:Oligometastasis
Colorectal cancer
Ablation
Stereotactic body radiation therapy
Liver metastases
Lung metastases
Descripción
Sumario:The prognosis for oligometastatic colorectal cancer has improved in recent years, mostly because of recent advances in new techniques and approaches to the treatment of oligometastases, including new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy (SBRT). There are several factors to consider when deciding on the better approach for each patient: tumor factors (metachronous or synchronous metastases, RAS mutation, BRAF mutation, disease-free interval, size and number of metastases), patient factors (age, frailty, comorbidities, patient preferences), and physicians' factors (local expertise). These advances have presented major challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases from colorectal cancer with a curative intention. In this review, we describe the different treatment options in patients with limited liver and lung metastases from colorectal cancer, and the possible combination of three approaches: systemic treatment, surgery, and local ablative treatments